Barrett's esophagus

Gastroesophageal Reflux Disease

Volumn , Issue , 2016, Pages 219-257

  Spechler, Stuart Jon ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051973922     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (147)

1. Spechler SJ, Goyal RK. The columnar lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996; 110:614-621.
2. Antonioli DA, Wang HH. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997; 26:495-506.
3. Spechler SJ. Laser photoablation of Barrett's epithelium: burning issues about burning tissues. Gastroenterology 1993; 104:1855-1858.
4. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
5. Spechler SJ. Short and ultrashort Barrett's esophagus: what does it mean? Semin Gastrointest Dis 1997; 8:59-67.
6. Hayward J. The lower end of the oesophagus. Thorax 1961; 16:36-41.
7. Kim SL, Waring PJ, Spechler SJ, Sampliner RE, Doos WG, Krol WF, Williford WO, and the Department of Veterans Affairs Gastroesophageal Reflux Study Group. Diagnostic inconsistencies in Barrett's esophagus. Gastroenterology 1994; 107:945-949.
8. Tytgat GNJ. Endoscopic features of the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26:507-517.
9. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295:476-480.
10. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 1996; 44:91-95.
11. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344:1533-1536.
12. Spechler SJ. The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut 1997; 41:710-711.
13. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-285.
14. Weston AP, Krmpotich P, Makdisi WE, Cherian R, Dixon A, McGregor DH, Banerjee SK. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996; 91:981-986.
15. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93:1033-1036.
16. McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic criterion. Gastrointest Endosc 1987; 33:413-416.
17. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer 1994; 74:556-564.
18. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218-228.
19. Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113:556-560.
20. Parsonnet J. Helicobacter pylori in the stomach-a paradox unmasked. N Engl J Med 1996; 335:278-280.
21. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 1998; 115:642-648.
22. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19(suppl 1):S37-S43.
23. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40:297-301.
24. O'Connor HJ, Cunnane K. Helicobacter pylori and gastro-oesophageal reflux disease- a prospective study. Ir J Med Sci 1994; 163:369-373.
25. Liston R, Pitt MA, Banerjee AK. Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Postgrad Med J 1996; 72:221-223.
26. Rosioru C, Glassman MS, Halata MS, Schwarz SM. Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications. Am J Gastroenterol 1993; 88:510-513.
27. Talley NJ, Cameron AJ, Shorter RG, Zinsmeister AR, Phillips SF. Campylobacter pylori and Barrett's esophagus. Mayo Clin Proc 1988; 63:1176-1180.
28. Ursua I, Ramos R, Val-Bernal JF. Helicobacter pylori in Barrett's esophagus. Histol Histopathol 1991; 6:403-408.
29. Loffeld RJLF, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol 1992; 87: 1598-1600.
30. Abbas Z, Hussainy AS, Ibrahim F, Jafri SM, Shaikh H, Khan AH. Barrett's oesophagus and Helicobacter pylori. J Gastroenterol Hepatol 1995; 10:331-333.
31. Ricaurte O, Fléjou JF, Vissuzaine C, Goldfain D, Rotenberg A, Cadiot G, Potet F. Helicobacter pylori infection in patients with Barrett's oesophagus: a prospective immunohistochemical study. J Clin Pathol 1996; 49:176-177.
32. Werdmuller BFM, Loffeld RJLF. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997; 42:103-105.
33. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442-1447.
34. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A. Prospective evaluation of the association of gastric H. pylori infection with Barrett's dysplasia and Barrett's adenocarcinoma. Gastroenterology 1998; 114:A703.
35. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF Jr. An inverse relation between CagAstrains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58:588-590.
36. Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA, Schnell J, Perez-Perez GI, Halter SA, Rice TW, Blaser MJ, Richter JE. The seroprevalence of CagApositive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115:50-57.
37. Graham DY, Yamaoka Y. H. pylori and CagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998; 3:145-150.
38. Matsukura N, Suzuki K, Kawachi T, Aoyagi M, Sugimura T, Kitaoka H, Numajiri H, Shirota A, Itabashi M, Hirota T. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980; 65:231-240.
39. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981; 13:931-939.
40. Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Goldfain D, Zeegen R. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centers. Gut 1985; 26:1319-1326.
41. Craanen ME, Blok P, Dekker W, Ferwerda J, Tytgat GNJ. Subtypes of intestinal metaplasia and Helicobacter pylori. Gut 1992; 33:597-600.
42. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57:324-329.
43. Tosi P, Filipe MI, Luzi P, Miracco C, Santopietro R, Lio R, Sforza V, Barbini P. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol 1993; 169:73-78.
44. Zwas F, Shields HM, Doos WG, Antonioli DA, Goldman H, Ransil BJ, Spechler SJ. Scanning electron microscopy of Barrett's epithelium and its correlation with light microscopy and mucin stains. Gastroenterology 1986; 90:1932-1941.
45. Jass JR. Mucin histochemistry of the columnar epithelium of the oesophagus: a retrospective study. J Clin Pathol 1981; 34:866-870.
46. Trier JS. Morphology of the columnar cell-lined (Barrett's) esophagus. In: Spechler SJ, Goyal RK, eds. Barrett's Esophagus: Pathophysiology, Diagnosis, and Management. New York: Elsevier Science, 1985:19-28.
47. Das KM, Prasad I, Garla S, Amenta PS. Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med 1994; 120:753-756.
48. Shields HM, Zwas F, Antonioli DA, Doos WG, Kim S, Spechler SJ. Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Dig Dis Sci 1993; 38:97-108.
49. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, Gramlich TL. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999; 30:288-294.
50. Salo JA, Kivilaakso EO, Kiviluoto TA, Virtanen IO. Cytokeratin profile suggests metaplastic epithelial transformation in Barrett's oesophagus. Ann Med 1996; 28: 305-309.
51. Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS. Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology 1997; 112:760-765.
52. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315:362-371.
53. Hassall E. Columnar-lined esophagus in children. Gastroenterol Clin North Am 1997; 26:533-548.
54. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau EL Jr. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9:23-27.
55. Winter C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-124.
56. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92(8):1293-1297.
57. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA: Prevalence of columnarlined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99:918-922.
58. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98:654-661.
59. Mulholland MW, Reid BJ, Levine DS, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989; 34:1329-1335.
60. Gillen P, Keeling P, Byrne PJ, Healy M, O'Moore RR, Hennessy TPJ. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg 1988; 75:540-543.
61. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983; 118: 543-549.
62. Zaninotto G, DeMeester TR, Bremner CG, Smyrk TC, Cheng SC. Esophageal function in patients with reflux-induced strictures and its relevance to surgical treatment. Ann Thorac Surg 1989; 47:362-370.
63. Gray MR, Donnelly RJ, Kingsnorth AN. Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus. Br J Surg 1991; 78: 1461-1466.
64. Öberg S, DeMeester TR, Peters JH, Hagen JA, Nigro JJ, DeMeester SR, Theisen J, Campos GMR, Crookes PF. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999; 117:572-580.
65. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103:1241-1245.
66. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64:526-530.
67. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287-1289.
68. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270:1320.
69. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-2053.
70. Spechler SJ. The frequency of esophageal cancer in patients with Barrett's esophagus. Acta Endoscopica 1992; 22:541-544.
71. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
72. American Cancer Society. Cancer Facts and Figures-1995. Atlanta: American Cancer Society, 1995.
73. Van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
74. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnarlined (Barrett's) esophagus. N Engl J Med 1985; 313:857-859.
75. Van der Veen AH, Dees J, Blankensteijn JD, van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989; 30:14-18.
76. Spechler SJ. Barrett's esophagus: should we brush off this ballooning problem? Gastroenterology 1997; 112:2138-2152.
77. Spechler SJ. Barrett's esophagus. Semin Oncol 1994; 21:431-437.
78. Ransom JM, Patel GK, Clift SA, Womble NE, Read RC. Extended and limited types of Barrett's esophagus in the adult. Ann Thorac Surg 1982; 33:19-27.
79. Harle IA, Finley RJ, Belsheim M, Bondy DC, Booth M, Lloyd D, McDonald JW, Sullivan S, Valberg LS, Watson WC, Frei JV, Slinger R, Troster M, Meads GE, Duff JH. Management of adenocarcinoma in a columnar-lined esophagus. Ann Thorac Surg 1985; 40:330-336.
80. Souza RF, Meltzer SJ. The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26:583-597.
81. Schmidt HG, Riddell RH, Walther B, Skinner DB, Riemann JF. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985; 110:145-152.
82. Spechler SJ. Endoscopic surveillance for patients with Barrett's esophagus: does the cancer risk justify the practice? Ann Intern Med 1987; 106:902-904.
83. Spechler SJ. Complications of gastroesophageal reflux disease. In: Castell DO, ed. The Esophagus. Boston: Little, Brown, 1992:543-556.
84. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105:40-50.
85. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, Rubin CE. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94:81-90.
86. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999; 49:170-176.
87. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96:1249-1256.
88. Lee RG. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients. Am J Surg Pathol 1985; 9:845-852.
89. Sontag SJ, Schnell TG, Kurucar C, O'Connell S, Levine G, Karpf J, Adelman K, Brand L, Seidel J. Barrett's high-grade dysplasia (HGD): surveillance endoscopy (EGD) once a year (yr) is sufficient in most patients (pts). Gastroenterology 1999; 116:A304-A305.
90. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19:166-178.
91. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, Rabinovitch PS, Reid BJ. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinomas. Cancer Res 1991; 51:5482-5486.
92. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998; 153:287-294.
93. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991; 51: 4495-4499.
94. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992; 102: 1220-1228.
95. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR, Roth JA. Mutations of p53 in Barrett's oesophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996; 111:323-331.
96. Khan S, Do KA, Kuhnert P, Pillay SP, Papadimos D, Conrad R, Jass JR. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998; 30:136-140.
97. Gimenez A, Minguela A, Parrilla P, Bermejo J, Perez D, Molina J, Garcia AM, Ortiz MA, Alvarez R, de Haro LM. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 1998; 15:83:641-651.
98. Kim R, Clarke MR, Melhem MF, Young MA, Vanbibber MM, Safatle-Ribeiro AV, Ribeiro U, Reynolds JC. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997; 42:2453-2462.
99. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg 1997; 225:17-30.
100. Cawley HM, Meltzer SJ, De Benedetti VMG, Hollstein MC, Muehlbauer KR, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrell J, Salages A, Bartsch H, Trivers GE. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115:19-27.
101. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flowcytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102:1212-1221.
102. Montgomery EA, Hartmann DP, Carr NJ, Holterman DA, Sobin LH, Azumi N. Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies. Am J Clin Pathol 1996; 106:298-304.
103. Cameron AJ. Barrett's esophagus and adenocarcinoma: from the family to the gene. Gastroenterology 1992; 102:1421-1424.
104. Woolf GM, Riddell RH, Irvine EJ, Hunt RH. A study to examine agreement between endoscopy and histology for the diagnosis of columnar lined (Barrett's) esophagus. Gastrointest Endosc 1989; 35:541-544.
105. Chobanian SJ, Cattau EL Jr., Winters C Jr., Johnson DA, Van Ness MM, Miremadi A, Horwitz SL, Colcher H. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus. Gastrointest Endosc 1987; 33:99-101.
106. Canto MIF, Setrakian S, Petras RE, Blades E, Chak A, Sivak MV Jr. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996; 44:1-7.
107. Stevens PD, Lightdale CJ, Green PHR, Siegel LM, Garcia-Carrasquillo RJ, Rotterdam H. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus. Gastrointest Endosc 1994; 40:747-749.
108. Falk GW, Catalano MF, Sivak MV, Rice TW, Van Dam J. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointest Endosc 1994; 40:297-312.
109. Kobayashi K, Izatt JA, Kulkarni MD, Willis J, Sivak MV Jr. High-resolution crosssectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results. Gastrointest Endosc 1998; 47:515-523.
110. Stepp H, Stroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience. Endoscopy 1998; 30: 379-386.
111. Panjehpour M, Overholt BF, Vo-Dinh T, Haggitt RC, Edwards DH, Buckley FP III. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996; 111:93-101.
112. Haringsma J, Tytgat GNJ. The value of fluorescence techniques in gastrointestinal endoscopy: better than the endoscopist's eye? I: The European experience. Endoscopy 1998; 30:416-418.
113. Marcon NE, Wilson BC. The value of fluorescence techniques in gastrointestinal endoscopy: better than the endoscopist's eye? II: The North American experience. Endoscopy 1998; 30:419-421.
114. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995; 9:451-454.
115. Spechler SJ. Comparison of medical and surgical therapy for complicated gastro esophageal reflux disease in veterans. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992; 326:786-792.
116. DeVault KR, Castell DO, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:1434-1442.
117. Marks RD, Richter JE, Rizzo H, Koehler RE, Spenney JG, Mills TP, Champion G. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907-915.
118. Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JRB, Hislop WS, Theodossi A, McFarland J, Watts DA, Taylor MD, Richardson PDI, and the Restore Investigator Group. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107:1312-1318.
119. Howden CW, Castell DO, Cohen S, Freston JW, Orlando RC, Robinson M. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155:1465-1471.
120. Spechler SJ. Laser photoablation of Barrett's epithelium: burning issues about burning tissues. Gastroenterology 1993; 104:1855-1858.
121. Sampliner RE. New treatments for Barrett's esophagus. Semin Gastrointest Dis 1997; 8:68-74.
122. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998; 93:332-335.
123. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98:2120-2128.
124. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
125. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231-1234.
126. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:989-991.
127. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93:711-716.
128. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335-1339.
129. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM, and the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91:1749-1757.
130. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GWB, Mirvish SS, Adrian TE. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996; 224:358-371.
131. Streitz JM, Andrews CW, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105:383-388.
132. Streitz JM, Ellis FH, Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93:911-915.
133. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:670-680.
134. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26:613-634.
135. Spechler SJ. Barrett's esophagus. Semin Gastrointest Dis 1996; 7:51-60.
136. Van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RW, Tilanus HW. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999; 94:1153-1160.
137. Sampliner RE. Ablative therapies for the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26:685-694.
138. Nishioka NS. Drug, light, and oxygen: a dynamic combination in the clinic. Gastroenterology 1998; 114:604-606.
139. Overholt BF, Panjehpour M. Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42:64-70.
140. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 1995; 42:59-63.
141. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996; 91:1719-1723.
142. Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348:584-585.
143. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114:448-455.
144. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49:1-7.
145. Guanrei Y, Songliang Q, Guizen F. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China. Endoscopy 1988; 20:95-98.
146. Brandt LJ, Kauvar DR. Laser-induced transient regression of Barrett's epithelium. Gastrointest Endosc 1992; 38:619-622.
147. Sampliner RE and the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93:1028-1032.